“So, we'd expect a very immaterial impact from tariffs that were proposed over the weekend for those countries.”

In context

“differentiated profiles for patients. Operator: Thank you. Our next question comes from Trung Huynh with UBS. Your line is open. You may ask your question. Trung Huynh: I just wanted to ask on the tariff news we saw emerge over the weekend. So, can you perhaps talk about your manufacturing footprint from China, Mexico and Canada? And there were also some discussions on it from the administration on transfer pricing. So, your IP for KEYTRUDA is based out of Ireland. How much of an impact could that have on Merck, if transfer pricing is also targeted? Caroline Litchfield: Thank you for the question, Trung. Our company, like many other companies, has a manufacturing footprint that really enables global supply. We have very low levels of manufacturing happening in China, in Mexico and Canada. So, we'd expect a very immaterial impact from tariffs that were proposed over the weekend for those countries. We will continue to assess the situation based on the different tariffs that are being proposed by the U.S. government, but remain confident in our supply chain and our ability to supply our medicines and vaccines around the world. Operator: Thank you. Our next question comes from Vamil Divan with Guggenheim. Your line is open. You may ask your question. Vamil Divan: Maybe just going back to WINREVAIR. Obviously, you have the positive news on the ZENITH and HYPERION. Just curious if it's changed in any way your expectations for Cadence. I think that's maybe underappreciated event later this year and other different indications. But just, I guess, Dean, curious if there's any readthrough we should be mean from the success you're having there. And then tied to that, if you can just comment”